MCID: MNC007
MIFTS: 54

Monocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Monocytic Leukemia

MalaCards integrated aliases for Monocytic Leukemia:

Name: Monocytic Leukemia 12 54 15 71
M5b Acute Differentiated Monocytic Leukemia 71
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD9CM 34 206.8
ICD10 32 C93 C93.9
UMLS 71 C0153903 C0598894 C1318544

Summaries for Monocytic Leukemia

Disease Ontology : 12 A myeloid leukemia that is characterized by a dominance of monocytes in the marrow.

MalaCards based summary : Monocytic Leukemia, also known as m5b acute differentiated monocytic leukemia, is related to acute monoblastic leukemia and leukemia, acute monocytic. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mesna and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Monocytic leukemia is a type of myeloid leukemia characterized by a dominance of monocytes in the... more...

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 620)
# Related Disease Score Top Affiliating Genes
1 acute monoblastic leukemia 33.6 KMT2A IL6 CXCL8 CSF2
2 leukemia, acute monocytic 33.5 TNF TLR4 KMT2A KAT6A IL6 CXCL8
3 neutropenia 30.6 ITGAM IL6 CSF2 CSF1
4 leukemia, acute lymphoblastic 30.2 KMT2A JUN ITGAM CSF2 CASP3
5 chickenpox 30.2 TNF IL6 IFNG
6 pancytopenia 30.2 KMT2A IL6 IFNG CSF2 CSF1
7 exanthem 30.2 TNF IL6 CXCL8 CSF2
8 herpangina 30.1 TNF TLR4 IL6
9 bone resorption disease 30.1 TNF IL6 CSF1
10 severe combined immunodeficiency 30.1 JUN IL6 IFNG CSF2 CSF1 CASP3
11 neurofibromatosis, type ii 30.0 TNF IL6 CXCL8
12 endocarditis 30.0 TNF IL6 IFNG CXCL8
13 crohn's colitis 30.0 TNF IL1B IFNG CXCL8
14 gastric ulcer 29.9 TNF IL6 IL1B CXCL8
15 graft-versus-host disease 29.9 TNF IL6 IL1B IFNG FAS
16 pulmonary tuberculosis 29.9 TNF TLR4 IL6 IFNG
17 respiratory failure 29.9 TNF JUN IL6 IL1B CXCL8
18 leukemia, chronic lymphocytic 29.9 TNF KMT2A IL6 FAS CSF2 CASP3
19 sarcoidosis 1 29.9 TNF ITGAM IL1B IFNG
20 obstructive jaundice 29.9 TNF TLR4 IL6 CXCL8
21 leukemia, acute myeloid 29.8 TNF KMT2A KAT6A JUN ITGAM IL6
22 hemophagocytic lymphohistiocytosis 29.8 TNF IFNG CXCL8
23 nervous system disease 29.8 TNF IL6 IL1B IFNG CSF2
24 ileus 29.8 TNF IL6 IL1B IFNG CSF2
25 hematologic cancer 29.8 KMT2A IL6 CSF2 CSF1 CASP3
26 neuritis 29.8 TNF IL6 IL1B IFNG CXCL8
27 central nervous system disease 29.7 TNF IL6 IL1B IFNG
28 cytomegalovirus infection 29.7 TNF IL6 IL1B FAS CXCL8 CASP3
29 t-cell leukemia 29.7 TNFRSF1A TNF JUN IL6 CSF2 CASP3
30 sarcoma 29.7 TNFRSF1A JUN IL6 FAS CXCL8 CSF2
31 visceral leishmaniasis 29.6 TNF TLR4 IL1B IFNG CXCL8
32 acute pancreatitis 29.6 TNF TLR4 IL6 IL1B CXCL8
33 allergic hypersensitivity disease 29.6 TNF TLR4 IFNG CXCL8 CSF2
34 mycobacterium tuberculosis 1 29.5 TNFRSF1A TNF TLR4 ITGAM IFNG
35 pertussis 29.5 TNF TLR4 JUN ITGAM IL6 IL1B
36 thrombocytosis 29.4 IL6 IL1B CSF2
37 gingival overgrowth 29.4 TNF IL6 CXCL8
38 crohn's disease 29.4 TNF TLR4 IL6 IL1B IFNG CXCL8
39 neuroblastoma 29.4 TNF JUN IL6 IFNG FAS CSF2
40 colon adenocarcinoma 29.3 TNFRSF1A TNF JUN FAS CXCL8 CASP3
41 toxic shock syndrome 29.2 TNF TLR4 IL6 IL1B IFNG CXCL8
42 meningitis 29.2 TNF TLR4 IL6 IL1B IFNG CXCL8
43 candidiasis 29.2 TNF TLR4 IL6 IL1B IFNG CXCL8
44 immune deficiency disease 29.1 TNFRSF1A TNF JUN IL6 IFNG FAS
45 aplastic anemia 29.0 TNF PPARG IL6 IL1B IFNG FAS
46 aspergillosis 29.0 TNF TLR4 IL6 IL1B IFNG CXCL8
47 lymphoma, non-hodgkin, familial 29.0 TNFRSF1A TNF KMT2A ITGAM IL6 FAS
48 autoimmune disease 28.9 TNF ITGAM IL6 IL1B IFNG FAS
49 leishmaniasis 28.8 TNFRSF1A TNF TLR4 ITGAM IL6 IL1B
50 thrombocytopenia 28.8 TNF TLR4 ITGAM IL6 IL1B IFNG

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 CASP3 CD14 CXCL8 FAS IL1B JUN
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 CASP3 CD14 CXCL8 FAS IL1B JUN
3 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 CASP3 CSF2 CXCL8 TNF

MGI Mouse Phenotypes related to Monocytic Leukemia:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 CAB39L CASP3 CSF1 CSF2 FAS IFNG
2 hematopoietic system MP:0005397 10.49 CAB39L CASP3 CD14 CSF1 CSF2 FAS
3 cellular MP:0005384 10.45 CASP3 CSF1 CSF2 FAS IFNG IL6
4 growth/size/body region MP:0005378 10.45 CASP3 CD14 CSF1 CSF2 FAS IFNG
5 homeostasis/metabolism MP:0005376 10.45 CASP3 CD14 CSF1 CSF2 FAS IFNG
6 immune system MP:0005387 10.44 CASP3 CD14 CSF1 CSF2 FAS IFNG
7 behavior/neurological MP:0005386 10.43 CASP3 CSF1 CSF2 FAS IFNG IL6
8 integument MP:0010771 10.37 CASP3 CSF1 CSF2 FAS IFNG IL1B
9 mortality/aging MP:0010768 10.35 CASP3 CD14 CSF1 CSF2 FAS IFNG
10 endocrine/exocrine gland MP:0005379 10.32 CASP3 CSF1 CSF2 FAS IFNG IL6
11 craniofacial MP:0005382 10.3 CASP3 CSF1 CSF2 FAS IFNG IL1B
12 nervous system MP:0003631 10.28 CASP3 CSF1 CSF2 FAS IFNG IL1B
13 liver/biliary system MP:0005370 10.24 CSF1 FAS IFNG IL6 JUN KAT6A
14 digestive/alimentary MP:0005381 10.19 CASP3 FAS IFNG IL6 KAT6A TLR4
15 adipose tissue MP:0005375 10.17 CD14 CSF2 IL6 PPARG TLR4 TNF
16 neoplasm MP:0002006 10.13 CSF2 FAS IFNG IL1B IL6 KMT2A
17 muscle MP:0005369 10.11 CASP3 CSF1 IFNG IL6 KMT2A PPARG
18 limbs/digits/tail MP:0005371 10.05 CSF1 FAS KAT6A KMT2A TLR4 TNF
19 hearing/vestibular/ear MP:0005377 10.04 CASP3 CSF1 FAS KMT2A PPARG TLR4
20 reproductive system MP:0005389 10.03 CASP3 CSF1 CSF2 FAS IFNG IL6
21 no phenotypic analysis MP:0003012 9.97 CASP3 CSF1 IFNG JUN KMT2A PPARG
22 renal/urinary system MP:0005367 9.97 CASP3 CSF2 FAS IFNG IL6 KMT2A
23 respiratory system MP:0005388 9.9 CASP3 CD14 CSF1 CSF2 FAS IFNG
24 skeleton MP:0005390 9.83 CASP3 CD14 CSF1 CSF2 FAS IFNG
25 vision/eye MP:0005391 9.32 CASP3 CSF1 FAS IFNG IL6 JUN

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 3 3375-50-6 598
2
Idarubicin Approved Phase 3 58957-92-9 42890
3
leucovorin Approved Phase 3 58-05-9 6006 143
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
6
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
10
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
11
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
12
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
13
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
14
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
15
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Melphalan Approved Phase 3 148-82-3 4053 460612
18
Carmustine Approved, Investigational Phase 3 154-93-8 2578
19
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
20
Hydroxyurea Approved Phase 3 127-07-1 3657
21
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
23
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
24
Daunorubicin Approved Phase 3 20830-81-3 30323
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
27
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
28
Histamine Approved, Investigational Phase 3 51-45-6 774
29
Cyproheptadine Approved Phase 3 129-03-3 2913
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
32 Lintuzumab Investigational Phase 3 166089-32-3
33
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
34 Staurosporine Experimental Phase 3 62996-74-1
35 Vaccines Phase 3
36 Antibodies, Monoclonal Phase 3
37 Immunoglobulins Phase 3
38 Antibodies Phase 3
39 Antineoplastic Agents, Immunological Phase 3
40 Gemtuzumab Phase 3
41 Alkylating Agents Phase 2, Phase 3
42 Folic Acid Antagonists Phase 3
43 Vitamin B Complex Phase 3
44 Vitamin B9 Phase 3
45 Folate Phase 3
46 Antirheumatic Agents Phase 3
47 Etoposide phosphate Phase 3
48 Adjuvants, Immunologic Phase 3
49 Analgesics Phase 3
50 Protective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
4 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
6 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
10 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
11 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
12 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
13 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
14 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
15 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
16 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
17 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
18 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
19 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
20 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
22 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
23 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
24 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
25 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
26 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
27 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
28 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
29 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
30 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
31 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
32 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
33 PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS Completed NCT00002567 Phase 2 etoposide
34 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
35 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
36 A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) Completed NCT00049179 Phase 2 cytarabine;gemtuzumab ozogamicin
37 A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older Completed NCT00023777 Phase 2 cytarabine;daunorubicin hydrochloride
38 A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60 Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
39 Pilot Study of Sodium Phenylbutyrate Plus Azacytidine Completed NCT00006019 Phase 2 azacitidine;sodium phenylbutyrate
40 A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00005801 Phase 2
41 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
42 Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study Completed NCT00003178 Phase 2 cladribine;idarubicin
43 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
44 Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
45 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
46 An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed NCT00775593 Phase 2 clofarabine;temsirolimus
47 A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen Completed NCT00070135 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
48 A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older Completed NCT00066794 Phase 2 cyclosporine;cytarabine;daunorubicin hydrochloride
49 Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study Completed NCT00006122 Phase 2 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
50 A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia Completed NCT00005962 Phase 2 cyclophosphamide;cytarabine;gemtuzumab ozogamicin;liposomal daunorubicin citrate;topotecan hydrochloride

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

40
Monocytes, Myeloid, Bone, Bone Marrow, T Cells, Skin, Endothelial

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 1941)
# Title Authors PMID Year
1
Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. 54 61
20427734 2010
2
The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway. 54 61
20438701 2010
3
Effect of Sargassum thunbergii on ROS mediated oxidative damage and identification of polyunsaturated fatty acid components. 54 61
20171254 2010
4
A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. 54 61
19506293 2009
5
Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-alpha through an ERK1/2-dependent pathway. 54 61
19556303 2009
6
Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells. 54 61
19333701 2009
7
Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-kappaB pathways. 54 61
19218821 2009
8
Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. 54 61
17870167 2008
9
A new simple multi-well plate-based assay for monocyte differentiation using human monocytic leukemia THP-1 cells. 54 61
17920620 2007
10
MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. 54 61
17694082 2007
11
LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22). 54 61
17532767 2007
12
Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. 54 61
17409565 2007
13
Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy. 54 61
17239427 2007
14
Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. 54 61
17139107 2006
15
Rolling and adhesion of apoptotic monocytes is impaired by loss of functional cell surface-expressed P-selectin glycoprotein ligand-1. 54 61
16839361 2006
16
ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. 54 61
16426569 2006
17
[Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration]. 54 61
16584580 2006
18
Modulation of autocrine TNF-alpha-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogen-activated protein kinases in THP-1 monocytic cells. 54 61
16497166 2006
19
[In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells]. 54 61
16552959 2005
20
MLL-MLLT10 fusion gene in pediatric acute megakaryoblastic leukemia. 54 61
16111539 2005
21
Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. 54 61
15984600 2005
22
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. 54 61
15767555 2005
23
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. 54 61
15680279 2005
24
Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. 54 61
15016631 2004
25
Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. 54 61
15313893 2004
26
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. 54 61
12738674 2003
27
A synergistic increase of apoptosis utilizing Fas antigen expression induced by low doses of anticancer drug. 54 61
13677932 2003
28
Regulation of A + U-rich element-directed mRNA turnover involving reversible phosphorylation of AUF1. 54 61
12819195 2003
29
The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. 54 61
12761814 2003
30
Differential effect of Bcl-xl over-expression on cell death of the monocytic leukemia cell line U937. 54 61
12553012 2002
31
MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. 54 61
11965546 2002
32
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. 54 61
11861382 2002
33
PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. 54 61
11861425 2002
34
Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. 54 61
11781384 2002
35
Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells. 54 61
11734301 2002
36
Identification of LIL-STAT in monocytic leukemia cells and monocytes after stimulation with interleukin-6 or interferon gamma. 54 61
11739196 2001
37
Histamine increases the expression of LOX-1 via H2 receptor in human monocytic THP-1 cells. 54 61
11728449 2001
38
Effect of trapidil on effector functions of monocytes related to atherosclerotic plaque. 54 61
11689197 2001
39
Apoptosis induction by epigallocatechin gallate involves its binding to Fas. 54 61
11478767 2001
40
Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. 54 61
11243405 2001
41
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). 54 61
10824998 2000
42
Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. 54 61
10639586 2000
43
Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. 54 61
10784404 2000
44
Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/macrophage THP-1 cells. 54 61
11426586 2000
45
Role of CD14 expression in the differentiation-apoptosis switch in human monocytic leukemia cells treated with 1alpha,25-dihydroxyvitamin D3 or dexamethasone in the presence of transforming growth factor beta1. 54 61
10547074 1999
46
Cytokine response of human macrophage-like cells after contact with polyethylene and pure titanium particles. 54 61
10537260 1999
47
Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. 54 61
10497217 1999
48
THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells. 54 61
10573130 1999
49
CD14 expression and production by human hepatocytes. 54 61
10488701 1999
50
9-cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. 54 61
10479651 1999

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.17 TNFRSF1A TNF TLR4 JUN ITGAM IL6
2
Show member pathways
13.96 TNFRSF1A TNF JUN ITGAM IL6 IL1B
3
Show member pathways
13.84 TNFRSF1A TNF TLR4 JUN IL6 IL1B
4
Show member pathways
13.69 TNFRSF1A TNF PPARG JUN IL6 IL1B
5
Show member pathways
13.63 TNFRSF1A TNF JUN ITGAM IL6 IL1B
6
Show member pathways
13.58 TNFRSF1A TNF TLR4 ITGAM IL6 IL1B
7
Show member pathways
13.53 TNFRSF1A TNF ITGAM IL6 IL1B IFNG
8
Show member pathways
13.47 TNFRSF1A TNF JUN IL6 IL1B FAS
9
Show member pathways
13.32 TNFRSF1A TNF TLR4 JUN IL1B IFNG
10
Show member pathways
13.31 TNFRSF1A TNF TLR4 JUN IL6 IL1B
11
Show member pathways
13.14 TNFRSF1A TNF TLR4 IL6 FAS CSF1
12
Show member pathways
13.13 TNFRSF1A TNF TLR4 JUN IL6 IL1B
13
Show member pathways
13.05 TNFRSF1A TNF JUN IL6 FAS CASP3
14
Show member pathways
13.03 TNF IL6 IL1B IFNG FAS CXCL8
15 13.01 PPARG JUN IL6 IFNG FAS CXCL8
16
Show member pathways
13 PPARG JUN ITGAM CSF2 CD14 CASP3
17
Show member pathways
12.98 TNFRSF1A TNF TLR4 JUN IL6 IL1B
18 12.97 TNFRSF1A TNF IL6 IL1B IFNG FAS
19 12.96 TNFRSF1A TNF JUN IL1B FAS CSF1
20
Show member pathways
12.93 TNF TLR4 IL6 IL1B IFNG CXCL8
21
Show member pathways
12.89 TNFRSF1A TNF JUN FAS CASP3
22
Show member pathways
12.86 TNFRSF1A TNF JUN IL1B IFNG FAS
23
Show member pathways
12.83 TNFRSF1A TNF JUN ITGAM FAS CASP3
24
Show member pathways
12.81 TNF TLR4 JUN IL6 IL1B IFNG
25
Show member pathways
12.8 TNFRSF1A TNF TLR4 IL6 IL1B
26
Show member pathways
12.78 TNFRSF1A TNF TLR4 JUN IL1B FAS
27
Show member pathways
12.77 TNF TLR4 JUN IL6 IL1B IFNG
28
Show member pathways
12.71 TNF IL6 IL1B IFNG CD14
29 12.69 TNFRSF1A TNF IL1B IFNG FAS
30
Show member pathways
12.69 TNF JUN IFNG FAS CSF2 CASP3
31 12.6 TNFRSF1A TNF TLR4 JUN IL1B CXCL8
32
Show member pathways
12.55 TNF JUN IL6 IL1B IFNG CXCL8
33
Show member pathways
12.54 TNF TLR4 JUN IL6 IL1B IFNG
34 12.5 TNFRSF1A TNF JUN IL6 CSF2
35
Show member pathways
12.5 TNFRSF1A TNF IL6 CXCL8 CSF1
36
Show member pathways
12.49 TNF IL6 IL1B IFNG CSF1
38
Show member pathways
12.47 TNF TLR4 JUN IL6 CXCL8 CD14
39 12.47 PPARG KMT2A ITGAM IL6 CXCL8 CSF2
40 12.47 TNFRSF1A TNF TLR4 JUN IL6 IL1B
41
Show member pathways
12.45 TNFRSF1A TNF TLR4 JUN ITGAM IL1B
42 12.44 TNF TLR4 JUN IL6 IL1B CXCL8
43
Show member pathways
12.42 TNFRSF1A TNF TLR4 IL1B IFNG FAS
44 12.4 TNF TLR4 FAS CASP3
45
Show member pathways
12.39 TLR4 FAS CD14 CASP3
46
Show member pathways
12.39 TNF IL6 IL1B IFNG CXCL8
47
Show member pathways
12.39 TNF JUN IL6 IL1B CXCL8
48
Show member pathways
12.39 TNFRSF1A TNF JUN FAS CASP3
49 12.39 TNFRSF1A TNF TLR4 IL6 IFNG CASP3
50 12.39 TNFRSF1A TNF TLR4 ITGAM IL6 IL1B

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TNFRSF1A TNF KIAA0100 IL6 IL1B IFNG
2 cell surface GO:0009986 9.8 TNFRSF1A TNF TLR4 ITGAM FAS CD14
3 extracellular space GO:0005615 9.65 TNFRSF1A TNF ITGAM IL6 IL1B IFNG
4 MOZ/MORF histone acetyltransferase complex GO:0070776 9.4 KAT6B KAT6A
5 death-inducing signaling complex GO:0031264 9.37 FAS CASP3
6 lipopolysaccharide receptor complex GO:0046696 9.26 TLR4 CD14
7 membrane raft GO:0045121 9.1 TNFRSF1A TNF ITGAM FAS CD14 CASP3

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.2 TNFRSF1A KMT2A IL1B IFNG FAS CD14
2 positive regulation of cell proliferation GO:0008284 10.16 JUN IL6 IL1B IFNG CSF2 CSF1
3 negative regulation of transcription, DNA-templated GO:0045892 10.14 TNF PPARG KAT6B KAT6A JUN IFNG
4 negative regulation of cell proliferation GO:0008285 10.13 PPARG JUN IL6 IL1B CXCL8
5 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 TNFRSF1A TNF TLR4 PPARG KMT2A KAT6B
6 positive regulation of apoptotic process GO:0043065 10.09 TNF PPARG JUN IL6 FAS CASP3
7 positive regulation of transcription, DNA-templated GO:0045893 10.08 TNF PPARG KMT2A KAT6B KAT6A JUN
8 positive regulation of gene expression GO:0010628 10.07 TNF TLR4 IL6 IL1B IFNG CSF2
9 positive regulation of protein phosphorylation GO:0001934 10.01 TNF IL1B IFNG FAS
10 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TNFRSF1A TNF TLR4 IL1B
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF TLR4 IL6 IL1B
12 response to lipopolysaccharide GO:0032496 10 TLR4 JUN IL1B CD14 CASP3
13 positive regulation of DNA-binding transcription factor activity GO:0051091 9.98 TNF PPARG IL6 IL1B
14 immune response GO:0006955 9.97 TNF TLR4 IL6 IL1B IFNG FAS
15 response to organic substance GO:0010033 9.96 TNF PPARG JUN CASP3
16 positive regulation of inflammatory response GO:0050729 9.96 TNFRSF1A TNF TLR4 IL1B
17 cellular response to mechanical stimulus GO:0071260 9.95 TNFRSF1A TLR4 IL1B FAS
18 cellular response to organic cyclic compound GO:0071407 9.91 TNF IL1B CASP3
19 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.91 TNFRSF1A TNF TLR4 CD14
20 regulation of insulin secretion GO:0050796 9.9 TNF IL1B IFNG
21 response to glucocorticoid GO:0051384 9.9 TNF IL6 CASP3
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF JUN IL6
23 positive regulation of neuron apoptotic process GO:0043525 9.89 TNF JUN CASP3
24 humoral immune response GO:0006959 9.89 TNF IL6 IFNG
25 positive regulation of phagocytosis GO:0050766 9.88 TNF IL1B IFNG
26 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR4 IL1B CD14
27 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR4 IL6 IL1B
28 extrinsic apoptotic signaling pathway GO:0097191 9.87 TNF IFNG FAS
29 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.87 TNF IL1B CSF2
30 positive regulation of interleukin-6 secretion GO:2000778 9.86 TNF TLR4 IL1B
31 inflammatory response GO:0006954 9.86 TNFRSF1A TNF TLR4 IL6 IL1B CXCL8
32 negative regulation of neurogenesis GO:0050768 9.85 TNF IL6 IL1B
33 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR4 IL1B
34 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF TLR4 IL1B IFNG
35 positive regulation of osteoclast differentiation GO:0045672 9.84 TNF IFNG CSF1
36 positive regulation of interferon-gamma production GO:0032729 9.84 TNF TLR4 IL1B CD14
37 positive regulation of chemokine production GO:0032722 9.83 TNF TLR4 IL6
38 positive regulation of glial cell proliferation GO:0060252 9.82 TNF IL6 IL1B
39 toll-like receptor 4 signaling pathway GO:0034142 9.81 TLR4 ITGAM CD14
40 positive regulation of amyloid-beta formation GO:1902004 9.81 TNF IFNG CASP3
41 astrocyte activation GO:0048143 9.8 TNF IL1B IFNG
42 monocyte differentiation GO:0030224 9.8 PPARG JUN CSF2
43 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR4 IL1B CD14
44 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNFRSF1A TNF IL6 IFNG CSF2
45 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.79 TNF IL1B IFNG
46 microglial cell activation GO:0001774 9.76 TNF JUN ITGAM IFNG
47 positive regulation of ceramide biosynthetic process GO:2000304 9.74 TNFRSF1A TNF
48 macrophage activation GO:0042116 9.74 TLR4 CSF2
49 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
50 cellular response to lipoteichoic acid GO:0071223 9.74 TLR4 CD14

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TNFRSF1A TNF TLR4 PPARG KMT2A KAT6B
2 identical protein binding GO:0042802 9.7 TNF TLR4 PPARG KMT2A JUN FAS
3 cytokine activity GO:0005125 9.17 TNF IL6 IL1B IFNG CXCL8 CSF2

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....